share_log

B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2

Benzinga ·  Aug 8, 2023 08:49

B of A Securities analyst Jason Gerberry downgrades FibroGen (NASDAQ:FGEN) from Neutral to Underperform and lowers the price target from $4 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment